JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vainchenker, William, Leroy, Emilie, Gilles, Laure, Marty, Caroline, Plo, Isabelle, Constantinescu, Stefan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773931/
https://www.ncbi.nlm.nih.gov/pubmed/29399328
http://dx.doi.org/10.12688/f1000research.13167.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773931/
https://www.ncbi.nlm.nih.gov/pubmed/29399328
http://dx.doi.org/10.12688/f1000research.13167.1

Ejemplares similares